Measure 
what matters.

Unlocking the full potential of precision medicine by measuring the cell-free transcriptome

Our cell-free
transcriptomic platform

Powered by RARE-seq

Resero Bio is building a next-generation liquid biopsy platform that combines advanced sample processing with AI/ML-driven analytics to measure gene expression signals non-invasively. Our integrated platform delivers biologically meaningful and clinically actionable insights into disease states from a simple liquid biopsy — without requiring tumor tissue or prior tumor sequencing.

Treatment response prediction
Risk stratification & prognostication
Molecular and/or histological subtyping
Pharmacodynamic effects
Molecular markers of toxicity
Mechanisms of therapeutic resistance
Cancer pathway activity
Tumor microenvironment (TME) composition

How it works

01.

Non-invasive sample collection

Plasma (1–4 mL)

Urine (10 mL)

02.

Targeted cell-free RNA sequencing

Broad panel targeting whole coding transcriptome (WCT) to maximize biological breadth (~20k genes)

Focused panel targeting rare abundance genes (RAGs) to maximize sensitivity (~5-7k genes)

03.

Bioinformatics insight engine

Quantify tumor burden

Classify disease state using hypothesis-driven biological signatures

Discover novel transcriptomic patterns

Detection is binary.
Biology is dynamic.

Our platform measures both – enabling non-invasive cancer detection while simultaneously interrogating disease phenotypes to unlock the full potential of precision medicine.